Beam Therapeutics shares surge 22.29% intraday after outlining 2026 pipeline updates and strategic priorities.

Beam Therapeutics surged 22.29% intraday after announcing pipeline updates and strategic priorities for 2026, including an accelerated FDA approval pathway for BEAM-302 and an extended cash runway through 2029. The stock’s rally aligns with news of $1.25 billion in cash reserves as of December 2025, reduced near-term financial risk, and a raised price target by Bernstein following the company’s progress in its Alpha-1 Antitrypsin Deficiency program. These developments collectively reinforced investor confidence in Beam’s pipeline advancements and financial sustainability, driving the sharp intraday increase.